Sienna Biopharmaceuticals has raised $40 million to advance its pipeline of clinical-phase aesthetic and dermatology assets.

It’s been a torrid few weeks for pressured OncoMed with trial woes compounded by partners walking away. Now, after hinting at cuts earlier this month, the…

After Jefferies analyst Biren Amin said last night that he thought Novartis would be presenting its midstage CAR-T blood cancer data from Juliet at a Swiss…

Daniel Teper has stepped down immediately as CEO of New York biotech Immune Pharma as he looks to head up its new oncology spinoff.

Fierce 15 company NGM Bio says it met its primary endpoint of reducing liver fat in NASH patients, with hints of antifibrotic activity, as the small biotech…

A phase 2 trial of Bristol-Myers' NASH candidate BMS-986036 met its primary endpoint.

Gilead Sciences has unveiled the first proof-of-concept data for its novel drug candidate for nonalcoholic steatohepatitis (NASH) as it tries to rebuild…

Tonix Pharmaceuticals has started recruiting military personnel into a phase 3 trial of its drug candidate for combat-related post-traumatic stress disorder (…

Despite reports that linked Novartis to cutting back on its cell therapy work, the Swiss major says it is going full steam ahead for its CAR-T research.

R&D